The American Journal of Managed Care

GoodRx to Match Novo Nordisk Price for Oral Semaglutide

Also for weight loss, GoodRx currently offers prefilled pens of semaglutide, sold as Ozempic and Wegovy, for $199 for the first 2 fills of 0.25-mg and 0.50-mg doses—in addition to the $39 per month fee for unlimited online care—and Zepbound (tirzepatide; Eli Lilly) at $299 for the first fill of a 2.5-mg vial and syringe. 5
TipRanks on MSN

GoodRx price target lowered to $2.60 from $3 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on GoodRx (GDRX) to $2.60 from $3 and keeps an Underperform rating on the shares. Heading
Rheumatology Advisor

Once-Daily Oral Wegovy Now Available for Weight Loss

Novo Nordisk announced the availability of Wegovy tablets, the first oral GLP-1 receptor agonist for weight loss and CV risk reduction.

GoodRx: The Tide Is Shifting Out Of This Company's Favor (Downgrade)

GoodRx (GDRX) downgraded due to falling users and policy risks. Learn about new revenue sources and competitive threats.
Fierce Healthcare

GoodRx taps former GoDaddy exec Scott Wagner as interim CEO as founders step down from top leadership role

Digital healthcare platform GoodRx taps former GoDaddy top exec Scott Wagner to serve as interim CEO as co-founders Doug Hirsch and Trevor Bezdek step down from the top leadership position. Hirsch and Bezdek transitioned into new roles as chief mission ...
Pharmaceutical Commerce

Pharma Pulse: GoodRx Rollout for Oral Wegovy; Major Reprieve for 340B Hospitals; Sanofi’s $2.5B AI Bet

In today’s Pharma Pulse, GoodRx slashes cash prices for the new Wegovy pill, a federal judge halts the 340B rebate pilot, and Sanofi doubles down on Earendil Labs’ AI platform for autoimmune breakthroughs.
Feedback